Infectious Diseases – Gabriela Burian, Sergey AKSENOV, Novartis AG

Abstract for “Vegf antagonist is used to treat chorioretinal and permeability disorders in paediatrics patients”

“The invention relates to the treatment of chorioretinal neovascular and permeability disorders in children. The invention provides a VEGF inhibitor for the treatment of children with ME or CNV. This method involves administering a VEGF antagonist to the child’s eye that does not enter the systemic circulation or quickly clears it. You can administer the VEGF antagonist intravitreally (e.g. You can inject it or apply it topically. In the form of eye drops. In addition, the invention allows the use of a VEGF antagonist to make a medication for the treatment of a child with a chorioretinal neovascular disorder or permeability disorder.

Background for “Vegf antagonist is used to treat chorioretinal and permeability disorders in paediatrics patients”

“DISCLOSURE of the INVENTION”

“DESCRIPTION DU DRAWINGS”

“MODES FOR CARRYING THE INVENTION”

“Comparative Example 1”.

“Comparative example 2”

“Example 1”

“Example 2”

“Ranibizumab Dose determination for treating children with Chorioretinal Neovascular or Permeability Disorders”

“Example 3”

“Example 5”

“Example 6”

“CONCLUSIONS”

“Example 7”

“Example 8”

“Example 9”

Summary for “Vegf antagonist is used to treat chorioretinal and permeability disorders in paediatrics patients”

“DISCLOSURE of the INVENTION”

“DESCRIPTION DU DRAWINGS”

“MODES FOR CARRYING THE INVENTION”

“Comparative Example 1”.

“Comparative example 2”

“Example 1”

“Example 2”

“Ranibizumab Dose determination for treating children with Chorioretinal Neovascular or Permeability Disorders”

“Example 3”

“Example 5”

“Example 6”

“CONCLUSIONS”

“Example 7”

“Example 8”

“Example 9”

Click here to view the patent on Google Patents.